What they were paid
Theravance Biopharma Director Compensation Table · the one fiscal year held| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2025 | $123,356 | $99,994 | $124,929 | $0 | $348,279 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Theravance Biopharma, Inc. DEF 14A filed April 28, 2026, accession 0001104659-26-050454, and prior-year filings. Open the filing on EDGAR.
Committees
FY2025 · as the proxy prints themAudit · Strategic Review Committee (Chair)
The rest of the Theravance Biopharma board
FY2025 · as the company reported each| Director | Role | FY2025 total |
|---|---|---|
| Dean J. Mitchell | Independent Director | $304,923 |
| Deepika R. Pakianathan, Ph.D | Independent Director | $317,423 |
| Donal O'Connor | Director | $319,923 |
| Eran Broshy | Independent Director | $305,923 |
| James Kelly | Independent Director | $55,000 |
| Jeremy T. Grant | Independent Director | $297,423 |
| Laurie Smaldone Alsup, M.D | Independent Director | $291,423 |
| Rick E Winningham | Director | $0 |
The full Theravance Biopharma compensation record
free company briefThis page is one director within Theravance Biopharma's record. The company brief lists every named executive and director, each linking to their own page.
Velarion Pro: every company page, peer tools and exports, one seat